Cevimeline (Evoxac) is a parasympathomimetic and muscarinic agonist, with particular effect on M1 and M3 receptors. It is used in the treatment of dry mouth associated with Sjögren's syndrome.
Mechanism of action
By activating the M3 receptors of the parasympathetic nervous system, cevimeline stimulates secretion by the salivary glands, thereby alleviating dry mouth.
Known side effects include nausea, vomiting, diarrhea, excessive sweating, rash, headache, runny nose, cough, drowsiness, hot flashes, blurred vision, and difficulty sleeping.
Contraindications include asthma and angle closure glaucoma.
Template:Navbox with collapsible sections